Levels of miR-126 and miR-218 are elevated in ductal carcinoma in situ (DCIS) and inhibit malignant potential of DCIS derived cells

A substantial number of ductal carcinoma in situ (DCIS) detected by mammography never progress to invasive ductal carcinoma (IDC) and current approaches fail to identify low-risk patients not at need of adjuvant therapies. We aimed to identify the key miRNAs protecting DCIS from malignant evolution, that may constitute markers for non-invasive lesions. We studied 100 archived DCIS samples, including pure DCIS, DCIS with adjacent IDC and pure DCIS from patients with subsequent IDC in contralateral breast or no recurrence. A DCIS derived cell line was used for molecular and cellular studies. A genome wide study revealed that pure DCIS has higher miR-126 and miR-218 expression than DCIS with adjacent IDC lesions or than IDC. The down-regulation of miR-126 and miR-218 promoted invasiveness in vitro and, in patients with pure DCIS, was associated with later onset of IDC. Survival studies of independent cohorts indicated that both miRNAs play a protective role in IDC. The clinical findings are in agreement with the miRNAs’ roles in cell adhesion, differentiation and proliferation. We propose that miR-126 and miR-218 have a protective role in DCIS and represent novel biomarkers for the risk assessment in women with early detection of breast cancer.

[1]  Ian Krop,et al.  Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  P. Prorok,et al.  Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness. , 2016, The New England journal of medicine.

[3]  G. Stein,et al.  Antagonizing miR-218-5p attenuates Wnt signaling and reduces metastatic bone disease of triple negative breast cancer cells , 2016, Oncotarget.

[4]  W. Barry,et al.  Patient Prognostic Score and Associations With Survival Improvement Offered by Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma In Situ: A Population-Based Longitudinal Cohort Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Bast,et al.  Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  T. Sørlie,et al.  Molecular Features of Subtype-Specific Progression from Ductal Carcinoma In Situ to Invasive Breast Cancer. , 2016, Cell reports.

[7]  Mirang Kim,et al.  Specific expression and methylation of SLIT1, SLIT2, SLIT3, and miR-218 in gastric cancer subtypes. , 2016, International journal of oncology.

[8]  E. Hwang,et al.  Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ. , 2015, Journal of the National Cancer Institute.

[9]  E. Santoni-Rugiu,et al.  Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma. , 2015, Anticancer research.

[10]  Ping Sun,et al.  Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ. , 2015, JAMA oncology.

[11]  Charles Swanton,et al.  Clinical management of breast cancer heterogeneity , 2015, Nature Reviews Clinical Oncology.

[12]  X. Shu,et al.  Tumor tissue microRNA expression in association with triple-negative breast cancer outcomes , 2015, Breast Cancer Research and Treatment.

[13]  Barbara L. Smith,et al.  RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  S. Capitani,et al.  In triple negative breast tumor cells, PLC-β2 promotes the conversion of CD133high to CD133low phenotype and reduces the CD133-related invasiveness , 2013, Molecular Cancer.

[15]  J. Reis-Filho,et al.  Progression from ductal carcinoma in situ to invasive breast cancer: Revisited , 2013, Molecular oncology.

[16]  George W. Sledge,et al.  A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast , 2013, Journal of the National Cancer Institute.

[17]  Andrea Sottoriva,et al.  The shaping and functional consequences of the microRNA landscape in breast cancer , 2013, Nature.

[18]  D. Altman,et al.  The benefits and harms of breast cancer screening: an independent review , 2012, British Journal of Cancer.

[19]  A. Schäffer,et al.  Tumorigenesis and Neoplastic Progression Single-Cell Genetic Analysis of Ductal Carcinoma in Situ and Invasive Breast Cancer Reveals Enormous Tumor Heterogeneity yet Conserved Genomic Imbalances and Gain of MYC during Progression , 2012 .

[20]  J. Reis-Filho,et al.  Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra‐tumour genetic heterogeneity and clonal selection , 2012, The Journal of pathology.

[21]  C. Croce,et al.  Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA , 2012, Proceedings of the National Academy of Sciences.

[22]  Carme Camps,et al.  microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. , 2011, Cancer research.

[23]  Volker Hovestadt,et al.  Molecular and Cellular Pathobiology MicroRNA Sequence and Expression Analysis in Breast Tumors by Deep Sequencing , 2011 .

[24]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[25]  D. Fan,et al.  MiR-218 Inhibits Invasion and Metastasis of Gastric Cancer by Targeting the Robo1 Receptor , 2010, PLoS genetics.

[26]  C. Croce,et al.  MicroRNAs in Cancer. , 2009, Annual review of medicine.

[27]  John D. Minna,et al.  Molecular Profiling of Breast Cancer Cell Lines Defines Relevant Tumor Models and Provides a Resource for Cancer Gene Discovery , 2009, PloS one.

[28]  Jun Yao,et al.  Regulation of in situ to invasive breast carcinoma transition. , 2008, Cancer cell.

[29]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[30]  F. Miller,et al.  MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. , 2000, Journal of the National Cancer Institute.